{"id":"tp-54575","type":"article-newspaper","title":"FDA Extends Capricor’s Deramiocel Review, Sets Nov. 22 Action Date","author":"Riza Dagoc","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/regulation/54575","datePublished":"2026-11-11T22:36:27.000Z","dateModified":"2026-11-11T22:36:27.000Z","language":"en","abstract":"The amendment includes two-year Phase 3 HOPE-3 extension data and an integrated efficacy summary across HOPE-2 and HOPE-3.","section":"Regulation","references":[]}